Combination therapies for cancer

A pharmaceutical composition comprising a PD-1 antagonist, wherein the pharmaceutical composition comprises one or both of a Compound A and a Compound B together with a pharmaceutically acceptable diluent or carrier, and wherein:

• the Compound A is a compound of structure (I):
• or a pharmaceutically acceptable salt or solvate thereof;
• and
• the compound B is a compound of structure (II):
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising an anti-human PD-1 antibody or an antigen binding fragment thereof together with a pharmaceutically acceptable diluent or carrier, wherein the combination therapy comprises the pharmaceutical composition and one or both of a Compound A and a Compound B,

• wherein the Compound A is a compound of structure (I):
• or a pharmaceutically acceptable salt or solvate thereof;
• and
• wherein the Compound B is a compound of structure (II):
• or a pharmaceutically acceptable salt thereof.

A method of treating cancer in a mammal comprising administering to said mammal a combination therapy, wherein the combination therapy comprises a therapeutically effective amount of a PD-1 antagonist and one or both of a therapeutically effective amount of a Compound A and a therapeutically effective amount of a Compound B, wherein:

• the Compound B is a compound of structure (II):
• or a pharmaceutically acceptable salt thereof;
• and
• the Compound A is a compound of structure (I):
• or a pharmaceutically acceptable salt or solvate thereof.